Orange CA 非小细胞肺癌临床试验
25项针对 非小细胞肺癌的研究正在 Orange及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
招募中2/3 期
- Providence St. Joseph Hospital, Orange
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- University of California, Irvine Health, Orange
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
招募中2 期
- University of California Irvine, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
- University of California Irvine, Orange
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
招募中1 期
- University of California - Irvine, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
招募中2/3 期
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- UC IRVINE Health, Orange
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- University of California Irvine Medical Center, Orange
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Orange
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
招募中3 期
- University of California Irvine, Orange
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
招募中2 期
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
招募中3 期
- Providence St. Joseph Hospital, Orange
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
招募中1/2 期
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
招募中1 期
- Research Site, Orange
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
招募中3 期
- UCI Chao Family Comprehensive Cancer Center, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
招募中1 期
- Research Site, Orange
A Study of VET3-TGI in Patients With Solid Tumors
招募中1 期
- UC Irvine Health, Orange
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
招募中观察性研究
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Orange
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Orange的其他研究
- 转移性癌症20 项研究
- 结直肠癌16 项研究
- 卵巢癌16 项研究
- 胰腺癌15 项研究
- 黑色素瘤14 项研究
- 肝癌（肝细胞癌）14 项研究
- 乳腺癌14 项研究
- 肺癌14 项研究
- 前列腺癌14 项研究
- 胃癌13 项研究
- 癌症（所有类型）13 项研究
- 急性髓系白血病13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。